The European Medicines Agency (EMA) has granted PRIME designation to Oculis‘ experimental treatment privosegtor for optic neuritis, a condition commonly seen in people with multiple sclerosis (MS). Optic neuritis, marked by inflammation of the optic nerve that carries signals between the eyes and the brain, can…
A new model of nerve fibers may serve as a platform to screen for experimental treatments that can promote myelin repair in multiple sclerosis (MS), a study showed. The model is made of soft micropillars around which myelin-producing cells can wrap myelin. Researchers found that some drugs tended to…
Quantum Biopharma has officially filed with the U.S. Food and Drug Administration (FDA) for clearance to begin a Phase 2 clinical trial of Lucid-MS, a “first-in-class” oral therapy designed to halt the progression of multiple sclerosis (MS) by protecting myelin, or the protective sheath around nerves in…
MS Canada is inviting cyclists across the country to take part in its 2026 MS Bike season, a series of fundraising rides aimed at supporting Canadians living with multiple sclerosis (MS). The annual MS Bike series brings together thousands of participants to ride scenic routes while raising money…
The cells that line the inside of the gut — known as intestinal epithelial cells — may play a key role in triggering inflammation that drives multiple sclerosis (MS), a study showed. The study found that these cells can activate a type of T-cell known as Th17 cells. These…
Get regular updates to your inbox.
